Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

Author： Postma Maarten J   Kruidhof Hanneke   Berg Lolkje TW de Jong-van den   Zeeuw Dick de  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.9, 2003-09, pp. : 1543-1550

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

By Carides George W.  

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Losartan: real benefits in RENAAL disease for patients with type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1290, 2001-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Irbesartan reduces progression of renal disease in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1290, 2001-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus: A Pharmacoeconomic Analysis of the Collaborative Atorvastatin Diabetes Study in the Belgian Population

By Annemans L.   Marbaix S.  

Clinical Drug Investigation, Vol. 30, Iss. 2, 2010-02 ,pp. : 133-142

Adis International

Access to resources Recommend Favorite

Beneficial Effect of Atorvastatin on Renal Function in Patients with Type 2 Diabetes

By Tanaka M  

The Journal of International Medical Research, Vol. 39, Iss. 4, 2011-07 ,pp. : 1504-1512

Field House Publishing

Access to resources Recommend Favorite